BCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioCryst Pharmaceuticals Inc. (BCRX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial growth, positive analyst sentiment, and promising product developments, making it a solid choice for long-term investment despite short-term technical overbought conditions.
The stock is showing a positive MACD histogram of 0.14 and expanding, indicating bullish momentum. RSI is at 85.151, signaling overbought conditions. Moving averages are converging, suggesting a potential breakout. Key resistance levels are at 7.985 and 8.359, while support levels are at 7.38 and 6.774.
Q4 2025 earnings showed a 209.1% YoY revenue increase and a 38% YoY increase in ORLADEYO revenue.
Launch of ORLADEYO pellets for children, strengthening its position in the HAE market.
Phase II trial for Navenibart showed a 92% reduction in attack rates with no safety signals.
Analysts have a positive outlook with price targets ranging from $17 to $32.
Insiders are selling, with a significant 1842.59% increase in selling activity over the last month.
Stock trend analysis predicts a potential decline of -1.54% in the next day, -3.95% in the next week, and -8.33% in the next month.
In Q4 2025, revenue increased by 209.1% YoY to $406.55 million, and ORLADEYO revenue grew by 38% YoY to $601.8 million. The company expects ORLADEYO revenues for 2026 to be between $625 million and $645 million. Gross margin improved to 96.1%, up 0.80% YoY. However, net income dropped to 0, reflecting a -100% YoY decline.
Analysts have a positive outlook on BCRX. Evercore ISI resumed coverage with an Outperform rating and a $17 price target, citing strong long-term growth potential. H.C. Wainwright raised its price target to $32, citing the approval of ORLADEYO for pediatric use. Analysts expect peak sales of $900M for ORLADEYO by 2029 and $1B for Navenibart in risk-adjusted sales.
